左西孟旦与多巴酚丁胺在急性失代偿性心力衰竭中的比较：随机对照试验的系统评价与荟萃分析
本研究为随机对照试验的系统评价与荟萃分析，比较左西孟旦与多巴酚丁胺在急性失代偿性心力衰竭（ADHF）伴射血分数降低患者中的疗效。结果显示，左西孟旦与30天全因死亡率显著降低及住院时间缩短相关。研究提示左西孟旦可能是特定ADHF患者的优选正性肌力药物，并支持未来临床指南考虑纳入。
要点
- 左西孟旦显著降低ADHF患者30天全因死亡率
- 左西孟旦缩短ADHF患者住院时间
- 左西孟旦可能是特定ADHF患者的优选正性肌力药物
核心结论
- 与多巴酚丁胺相比，左西孟旦在ADHF患者中与30天全因死亡率显著降低和住院时间缩短相关
- 左西孟旦可能成为特定ADHF患者的优选正性肌力药物，值得未来指南考虑
研究设计与样本
- 系统评价与荟萃分析
- 纳入随机对照试验
- 研究对象为急性失代偿性心力衰竭伴射血分数降低患者
主要发现
- 左西孟旦组30天全因死亡率显著低于多巴酚丁胺组
- 左西孟旦组住院时间较短
- 左西孟旦的药理特性可能带来生存获益
关键数值与推荐
- 原文未提供具体数值
- 原文未提供风险比或置信区间
- 原文未提供死亡率具体百分比
临床怎么用
- 在特定ADHF患者中可考虑优先使用左西孟旦
- 临床决策需结合患者个体情况
- 未来指南制定时可参考此证据
局限性
- 原文未报告具体局限性
- 需进一步开展成本效益分析
- 特定亚组的研究证据尚不足
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Dobutamine is widely used as inotropic support in acute decompensated heart failure (ADHF) with reduced ejection fraction, but its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative due to its distinct pharmacological profile and possible survival benefit, yet comparative evidence has been inconclusive. WHAT THIS STUDY ADDS This systematic review and meta-analysis of randomised controlled trials demonstrates that levosimendan is associated with a significant reduction in 30-day all-cause mortality and a shorter length of hospital stay compared with dobutamine in patients with ADHF. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings suggest that levosimendan may be a preferred inotropic agent in selected patients with ADHF and support its consideration in future clinical guidelines. Further cost-effectiveness analyses and studies in specific subgroups are warranted. Introduction ...
引用
- Heart：Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。